Sell Data to AI
Home Log in AI Data Value Score Pricing API documentation MCP server for AI assistants 26 US company lists Niche lists
For brokers
The Sell Data to AI Rules How to become an AI data broker Data broker business model Buyer programs compared Qualify a company AI training data companies
For data companies
Firmographic data providers Company data API
Seller guides
How to sell data to AI companies Is it legal? Anonymize before selling Score, then make it safe to sell FAQ and glossary
Score any company Check your own company
For data brokers and partnership teams

List of US biotech companies, scored by data value

Last updated: 8 October 2026

For brokers, referrers and the partnership teams at data companies. A list of biotech companies gives you names. To introduce one to an AI data buyer you also need to know which segment it is in, which records it likely holds, whether it is still operating, and what its IP and regulatory position allows. This page covers all four, with a preview drawn from our scored segment of US labs, CROs and life-science companies.

4 segmentstherapeutics, tools, diagnostics, synthetic biology
From $199one-time: the top 3,000+ by AI Data Value Score, selected from 22,954 US domains in this sector of our index
4 statusesactive, winding down or acquired, parked, unreachable
About 20 sto check a target against published buyer rules

Already have your own list of biotech domains? Score them through the API in batches of up to 100, on plans from $99 a month. Compare plans.

The data AI labs pay most for, identified for every company

Not all company data is worth the same. Our research shows AI labs pay most for the records of real work, held in the systems below. We identify which of these systems each company runs, and it is one of the most important factors in the AI Data Value Score.

Work tickets and internal wikiJira, Confluence
Customer support ticketsZendesk, Intercom
CRM recordsSalesforce, HubSpot
Calls and meetingsZoom, Gong
Contracts and documentsDocuSign, Box
Design filesFigma, Miro
Finance and ERP recordsNetSuite, QuickBooks
Code with historyGitHub, GitLab
Work email and documentsMicrosoft 365, Google Workspace
HR and recruiting recordsWorkday, Greenhouse
Training and course contentLearning platforms, course libraries
Fleet and sensor dataFleet and machine data
Clinical and lab systemsPatient and lab records
Human-era archivesYears of records written before 2023

Every company comes with the systems we identified, shown as tags. Company level only: we show which systems a company runs, never what is inside them.

What the top 4,200 labs, CROs and life-science companies hold

Share of the 4,200 companies in this list with each data type. Among them, 15% run systems for CRM records, 11% for contracts and documents, 10% for work tickets and internal wikis, and 64% have been online for 10 years or more before 2023.

84%run data systems we identified
29%run systems beyond work email, such as CRM, tickets or contracts
64%online 10+ years before 2023 (human-era archives)
27%online 20+ years before 2023

Data types, by share of companies

Work email and documents83% · 3,492
CRM records15% · 621
Contracts and documents11% · 464
Work tickets and internal wiki10% · 418
Calls and meetings8% · 330
Customer support tickets2% · 103
Finance and ERP records2% · 69
Design files2% · 65
HR and recruiting records<1% · 33
Clinical and lab systems<1% · 25
Training content<1% · 4
Code with history<1% · 1

Most common systems

Microsoft 36564%Google Workspace27%Jira / Confluence9%DocuSign9%HubSpot9%Salesforce7%Zoom6%Box2%Zendesk2%Webex1%NetSuite1%Slack1%Notion1%Miro1%

Data signals on their websites

Lab, study and R&D records100%
Work email and documents83%
Recruiting and hiring records35%
Order and transaction records30%
Support tickets and chat transcripts25%
CRM and sales records25%
Knowledge base, SOPs and documentation24%
Customer accounts and portal activity21%

Counted over the companies a buyer gets in this list: verified active, checked for fit with the industry, highest AI Data Value Score first. Company level only: we show which systems a company runs, never what is inside them.

Narrower niche lists for this field

Niche lists go deeper than a sector list. Every company domain is verified active, each company was checked for fit with the niche, and companies are ranked by the AI Data Value Score. $2,500 per list, or $9,900 for 90 days of exclusive access.

Start here

Why a plain list of biotech companies is not enough

Searches for a list of biotech companies, or a list of biotech companies in the USA, come from investors, job seekers, suppliers and students, and the lists that answer them are built for those readers: names, funding stages, headquarters, perhaps a pipeline chart. City versions are common too, for well-known clusters such as Boston and San Diego. This page does not split companies by city, and it does not try to count biotech companies anywhere.

A broker, or a sourcing team at a data company, needs different columns. Is the company still operating? Has it existed long enough to hold several years of records? Which of its records are its own, and which belong to partners, licensors or patients? Does it meet the size and location rules that buyer programs publish? Without those columns, every name on a list is a guess, and every introduction costs you credibility with the buyer when it fails review.

Our list answers the first set of questions at company level. It is one of our 26 US industry lists and covers US labs, CROs and life-science companies. Every company domain on it is verified active and every company is checked for fit with its industry. A verified active domain resolves, is not expired, is not parked and shows no error or placeholder page. The list keeps growing as more companies pass those checks, so the live count is on the lists page, not on this one. Companies from all four biotech segments below appear in it, next to testing labs and contract research organizations. Each company carries an AI Data Value Score, a grade, the data it likely holds, its history and an activity status. Everything after that is judgment, and most of this page is about that judgment.

Biotech segments

Four biotech segments, and the records each one keeps

Biotech is not one kind of company. The segment predicts what the company writes down, who else has rights in it, and how close its records sit to its main asset.

Therapeutics

Companies developing medicines: small molecules, antibodies and other biologics, cell and gene therapies, vaccines.

Records

Discovery and assay data, notebook entries, preclinical study files, process development and manufacturing records, regulatory correspondence, clinical operations often run through CROs.

The R&D record sits next to the pipeline, the company's main asset. Look first at quality, operations and documentation.

Tools and platforms

Companies that sell to other scientists: reagents and kits, instruments and lab equipment, research software and computational platforms.

Records

Technical support tickets, application notes and protocols, knowledge bases, customer portals and orders, product test records, software code and issue histories.

Often the most practical segment: much of the record is about how customers use products, not about a private pipeline.

Diagnostics

Companies that develop and run tests: lab-developed tests, test kits, genomic and molecular testing services.

Records

Assay development and validation, quality system records, design files for kits, lab operations and scheduling, support for ordering clinics and labs.

Any lab reporting results on patients holds patient data. The non-patient record, validation and quality, is the possible scope.

Synthetic biology

Companies that engineer organisms and DNA: strain and enzyme engineering, DNA design and synthesis, biomanufacturing.

Records

Design, build and test cycles, strain and construct records, fermentation and scale-up notes, automation logs, design software and scripts.

Highly structured and experimental, and close to trade secrets. Some technology may also raise export control questions.

What a biotech's operating record looks like, segment by segment

Read across a row to see how the same kind of record changes from segment to segment. The row labels match the likely data assets an AI Data Value Score can show, so you can line up a scored company against this table quickly.

Record typeTherapeuticsTools and platformsDiagnosticsSynthetic biology
Lab, study and R&D recordsDiscovery, assay and preclinical work, close to the pipelineApplication development, product testing, method notesAssay development and validationDesign, build and test cycles, strain records
Knowledge base, SOPs and documentationGLP and GMP procedures, process documentationProduct manuals, protocols, application notes, internal QC proceduresQuality system, lab procedures, kit instructionsBiomanufacturing and lab automation procedures
Support tickets and chat transcriptsFew, mostly with partners and vendorsOften large: technical questions from scientists using productsQuestions from ordering clinics and labs, often with patient detailsCustomer projects at platform companies
Project histories and case filesProgram management, partner governanceProduct development and release historiesTest launch and validation projectsCustomer and partner programs
Code with commit and issue historyAnalysis and bioinformatics pipelinesInstrument software, analysis tools, platform codeBioinformatics pipelines, lab softwareDesign software, automation scripts

Typical patterns, not a description of any company. A given company may hold more, less or none of these.

Why buyers care

Why AI data buyers may look at biotech records

Biotech is built on expert judgment that rarely reaches the public record. That is what makes some of its operating records interesting, and why the qualification work on this page matters.

Failures are written down

Published papers report what worked. Internal records show what was tried and dropped, and why. Negative results almost never get published, so that part of the record is rare.

Decisions repeat in a structure

Validation reports, deviation records and support tickets follow templates, so the same kind of expert decision appears many times, made by different people.

Experts can build evaluations

Practitioners say evaluations are worth about 10x raw data, and full environments reach 6 to 8 figures. Both need scientists who know the work, which biotechs employ.

Tools companies deserve a special mention. A reagent or instrument maker answers technical questions from scientists every day: why an assay failed, how to adapt a protocol, what a strange reading means. Those answers, written by application scientists over many years, are a record of expert troubleshooting that is mostly about the customer's problem rather than the company's secrets. That does not make them free to license. Customer names, customer data and anything covered by customer contracts still need to come out, and the company decides whether it wants to do this at all. But it explains why tools companies often look strong on paper.

Therapeutics developers are the opposite case. Their R&D record may be the most valuable thing they own, and it is tied to patents, partners and, later, to patients. A broker who leads with that record will rarely get past the first call. A broker who asks about quality systems, training, project management and internal documentation, the things every developer builds and few treat as secret, has a more realistic opening. For more on how buyers weigh raw records against evaluations, read raw data vs evaluations vs environments.

IP and regulatory limits

Eight limits to raise before any introduction

General information, not legal advice. Each card ends with the question to put to the company's counsel. You do not need the answers to introduce a company, but you do need to know the questions exist, so you never pitch what cannot be sold.

Patents

Disclosing unpublished results or methods may affect patent positions, including inventions not yet filed.

Ask IP counselCould anything in scope reveal an unfiled invention, a target or a compound?

Trade secrets

Processes, strains, cell lines and formulations are often protected as secrets, which only works while they stay secret.

Ask IP counselWhich records describe processes the company protects as trade secrets?

Partner agreements

Collaborations, licensed-in technology and co-development deals usually define who owns data and results.

Ask counselWhich agreements give a partner or licensor rights over data the company holds?

Grants and sponsored research

Government grants and university agreements can set terms on data, results and how they are shared.

Ask counselDo any grant or sponsored research terms restrict use or licensing?

Patient data and HIPAA

Diagnostics labs and clinical work involve patient data. HIPAA's de-identification standard names Safe Harbor and Expert Determination.

Ask counselDo any systems hold patient data, and can they be fully excluded?

Genetic data

Some states have laws that deal specifically with genetic information, on top of general health privacy rules.

Ask counselDoes the company hold genetic data about people, and which state laws apply?

GxP records

GLP, GMP and GCP rules, and 21 CFR Part 11 for electronic records, govern how regulated records are kept and changed.

Ask counsel and QADoes copying regulated records affect retention, audit trails or validated systems?

Export controls

Some biological materials, equipment and technical data fall under export control rules, which can reach data shared abroad.

Ask counselDoes any record contain controlled technical data, and where would the buyer process it?

Staff names are everywhere. Notebook entries, tickets and validation reports carry the names of the scientists who wrote them. What staff must be told, and which names come out, is one more question for counsel. For R&D records in more depth, read labs, chemistry and semiconductors. For patient data, read healthcare data and AI training.
Buyer rules

Published buyer rules, applied to a biotech

As published, checked 7 October 2026. Company ranges are what each program states, not offers. Referral amounts are paid only under each program's own terms.

micro1$100K-$2M+"for approved data packages"; referrers "earn $50,000", "no cap"
Published fit
30+ employees (the referral posting says 30 to 200), US first, primarily English.
For a biotech
A seed-stage company with a handful of scientists will miss the size rule. A tools company or a later-stage developer may not.
Terms to know
Paid after onboarding plus a minimum revenue threshold. Sole discretion, clawbacks, no sharing payouts with companies, no posing as micro1's partner.
Mode$100K-$5M"Earn $50K per referral"
Published fit
20+ full-time US office employees and several years of records.
For a biotech
Count full-time US employees, not contractors or partner staff. Look for years of records the company still holds, not a founding date.
Typical timing
Practitioners say deals take 60 to 90 days to close.

To see which published rules a specific company meets, use the check against buyer rules: it reads the company's public pages and compares team size, location, history and systems with the published rules of micro1 and Mode, with quotes.

Qualification

How to qualify a biotech as a data partner

Six steps, cheapest first. None of them involves seeing a record, and the first four take minutes per company.

  1. Place it in a segmentTherapeutics, tools and platforms, diagnostics or synthetic biology. The segment tells you where the sellable record is likely to be, and where it is not.
  2. Check status and historyThe AI Data Value Score shows whether the company is active, winding down or acquired, parked or unreachable, and how long it has been online. A company that is not active is a different conversation.
  3. Read the likely data assets and gradeLine the likely data assets up against the segment table above. Documentation, support and project histories are easier to scope than R&D records.
  4. Check size and locationRun the company through the check against buyer rules and qualify the target in about 20 seconds. If its pages say little, the result says "not stated" instead of guessing.
  5. Map the IP and partner positionPatents, trade secrets, partner rights, grants, patient and genetic data. You do not answer these; you make sure the company knows to ask them before scope is discussed.
  6. Introduce through the programUse the buyer program's own referral process, disclose your role, and stay out of the data. See data referral programs for how the published programs pay.
ExampleAI Data Value Score
71
bayline-assays.exampleGrade B · Active · online since 2001Life sciences, pharma and labs · United States

Likely data assets

Support tickets and chat transcriptsKnowledge base, SOPs and documentationLab, study and R&D recordsOrder and transaction records

Factor groups

History strong
Scale medium
Knowledge assets strong
Operational systems medium
Customer systems strong
Organization medium
Industry value strong
Expertise strong
Activity status active
Grade B
Fictional company and values, for illustration only. The .example domain is reserved and does not exist.

How the AI Data Value Score helps

The score is a triage tool. It ranks companies from 0 to 100 for data value to AI buyers, gives a grade, lists the data the company likely holds and shows its history and activity status. It covers nine factor groups: history, scale, knowledge assets, operational systems, customer systems, organization, industry value, expertise and activity status. It is built on our index of 120 million domains, 99.99% of the active internet, with domain history.

In the example, a broker sees a long history, strong documentation and customer systems, and support tickets as a likely asset. That pattern fits a tools company. The next steps are human ones: confirm the segment on the company's site, run the check against buyer rules, and think about which of those support records involve customer data.

What the score does not do matters as much. It is an estimate from public signals, not a valuation, not an offer and not proof that the company wants to sell anything. It cannot see inside a company's systems or contracts. Use it to decide which companies to look at first, then do the qualification work. You can try it on any company in the free demo, which is limited per day.

What each activity status means for a broker

Every AI Data Value Score shows one of four statuses. In biotech, where companies are acquired, merged and wound down often, it is the field to read before any other.

StatusWhat it tells youWhat to do next
ActiveThe company appears to be operating under its own name.The normal path: segment, likely data assets, buyer rules, then an introduction through the program.
Winding down or acquiredThe people who could sign may have changed. The records may now sit with an acquirer, a parent company or whoever handles the wind-down.Find out who controls the records before anything else. Buyers have bid for archive data in this situation; see the Spirit Airlines case below.
ParkedThe domain is parked rather than running a company website.Not a partner as it stands. Check whether the business moved to another name or domain.
UnreachableThe company's website was not reachable when it was last scored.Check again later before you draw a conclusion either way.
Archive deals are real. Our Shutdown Radar lists US companies showing signals of winding down, each with the evidence. In August 2026, Google agreed to pay $10M for bankrupt Spirit Airlines' internal data, and micro1 filed a $12.5M competing bid; approval was not confirmed as of 7 October 2026. We mention it as context only. Our product shows activity status company by company, on every score.
Preview

Finding biotech companies in the free preview

The free preview of US labs, CROs and life-science companies shows 5 visible rows. They are companies checked for this industry, and they can change, so we do not copy them onto this page. See the live preview for the rows as they stand today.

Each visible row shows the fields every company on the list carries: the company website, its AI Data Value Score and grade, its activity status, the year it came online and the data it likely holds. The preview labels every company "Life sciences, pharma and labs". It does not say which biotech segment a company belongs to, and we will not guess at that on a public page.

That sorting is your first job as a broker. Open each company's own website and place it in one of the four segments above: therapeutics, tools and platforms, diagnostics or synthetic biology. It takes a few minutes per company, and it changes what you look for next. A tools company points you toward support tickets and documentation. A therapeutics developer points you toward R&D records, and toward the patent and partner questions that come with them.

All four biotech segments sit in the list, next to testing labs and contract research organizations. To reach the ones the preview does not show, work through the list itself, bought once as a download, filter by score, and place each company in a segment yourself using the tiles above. For contract research organizations in the same list, see the list of contract research organizations.

What the one-time file holds

The one-time download holds the top 3,000+ by AI Data Value Score, selected from 22,954 US domains in this sector of our index: the companies most likely to hold what AI buyers ask for, which is where most brokers start. It gives you a short, strong pipeline to work by hand. Smaller and younger biotechs often sit further down the ranking. If you plan to filter by segment yourself and do not want to miss a promising synthetic biology or diagnostics company below the cut, collect the domains of the biotechs you find yourself and score them through the API in batches of up to 100 domains, on any plan. Live counts for every list are on the lists page.

Company-level information from public signals only; scores are estimates, not valuations or offers, and do not mean a company wants to sell data.

Partner signals

Stronger and weaker signs in a biotech data partner

No single signal decides anything. Taken together, they tell you whether a company is worth a buyer's review time, and yours.

Stronger signs

  • Active status and a long history online, which usually means years of records still held
  • Likely data assets include documentation, support tickets or project histories, not only CRM and orders
  • A tools or platform business, where much of the record concerns customer use rather than a private pipeline
  • A US team that meets the size rule of at least one published program
  • Independent, or with a clear owner who can sign for the records
  • Work that can be described without patient data, partner data or unfiled inventions

Weaker signs

  • Parked or unreachable, or acquired with the records now held by a parent
  • A very young company with a small team and little history of records
  • Records centered on an unpatented pipeline the company must keep secret
  • A diagnostics lab whose operational records are mostly patient results
  • Most R&D done under partner agreements that give the partner rights in the data
  • Only CRM and order records among the likely data assets
Plans

Getting the list once as a file, and scoring your own domains

Last updated: 8 October 2026. A free preview is public, with 5 companies checked for this industry visible. The US labs, CROs and life-science companies list can be bought once as a file, from $199 a list (the 3,000+ highest-scored companies). The API plans below do not include lists: they score the domains you send and differ only by lookups.

Basic

$99a month
  • 5,000 lookups a month
  • Score any biotech already on your own list, with all response fields
  • Batch scoring of your own domain lists, up to 100 domains per call
Choose Basic

Pro

$299a month
  • 25,000 lookups a month
  • Batch scoring of your own domain lists, up to 100 domains per call
  • The same response fields as Basic; only the lookups differ
Choose Pro

Scale

$799a month
  • 100,000 lookups a month
  • Batch scoring of your own domain lists, up to 100 domains per call
  • The same response fields as Basic; only the lookups differ
Choose Scale

Company lists: sold only as one-time files, with or without a plan. Each list you choose holds the top 3,000+ companies of a US sector by AI Data Value Score, and more lists cost less each.

Purchase1 list2 lists3 lists5 listsEach further listAll 21 lists
One-time price$199$379$539$799+$199$3,900

The checkout shows the exact price for the lists you pick. Download links are emailed right after payment, valid 30 days with 10 downloads per file; the files are a snapshot with no updates. To score biotechs that are not in the file, send their domains to the API in batches on any plan.

Buy the US labs, CROs and life-sciences list: from $199 a list (the 3,000+ highest-scored companies)

Pay by PayPal or card. On a plan, your API key appears in your dashboard after payment, not by email. There is no free plan and no trial; the demo is free and limited per day. Company-level data only, never contacts. Full details on the pricing page and in the API documentation.

FAQ

Questions about biotech lists and data partners

Is this a list of every biotech company in the USA?

No. We do not publish a count of biotech companies in the USA or in any city. Biotech companies sit in our US labs, CROs and life-science companies list, one of 26 US industry lists, where every company domain is verified active and every company is checked for fit with its industry. Every company on it is scored. Therapeutics, tools, diagnostics and synthetic biology companies all appear in it, next to testing labs and contract research organizations.

Do you have a list of biotech companies in Boston or San Diego?

No. We do not build city lists. The segment covers US companies, and each company carries the same fields wherever it is based: AI Data Value Score, grade, likely data assets, history and activity status.

Which kind of biotech company makes the best AI data partner?

There is no single answer, and no buyer publishes one. Tools and platform companies often hold large customer-facing records such as support tickets and documentation, which sit further from a proprietary pipeline. Therapeutics developers hold rich R&D records, but those sit closest to patents and partner rights. Qualify each company on its own records, size and status.

Can a biotech license R&D records without harming its patents?

That is a question for the company’s IP counsel, not for a broker. Disclosing unpublished results or methods may affect patent positions and trade secrets, and collaboration or grant terms may give others rights in the data. General information, not legal advice.

What does the AI Data Value Score tell me about a biotech?

A score from 0 to 100 for data value to AI buyers, with a grade, the data the company likely holds, its history and an activity status: active, winding down or acquired, parked, or unreachable. It covers nine factor groups: history, scale, knowledge assets, operational systems, customer systems, organization, industry value, expertise and activity status. It is an estimate from public signals, not a valuation or an offer.

What should I do with a biotech marked winding down or acquired?

Treat it as a different track. The people who could sign may have changed, and the records may now belong to an acquirer, a parent company or whoever is handling the wind-down. Find out who controls the records before you introduce anyone. The status appears on every score, and the Shutdown Radar (https://www.selldatatoai.com/shutdown-radar/) lists US companies showing signals of winding down.

How do I get more than the preview?

Buy the US labs, CROs and life-science companies list once, from $199 a list (the 3,000+ highest-scored companies). The file is a CSV snapshot with no updates, and download links are emailed right after payment, valid 30 days with 10 downloads per file. That one-time file is the only way the list is sold. The API plans score the domains you send and do not include lists. Basic $99 a month: 5,000 lookups. Pro $299 a month: 25,000 lookups. Scale $799 a month: 100,000 lookups. Batch scoring of your own domain lists is on every plan, up to 100 domains per call. Payment is by PayPal or card; on a plan, the key appears in your dashboard after payment.

Does the list include founders, scientists or contact emails?

No. Everything is company level only. We do not publish or sell names, emails or phone numbers of people.

Qualify biotech companies before you introduce them

Start with the free preview, score any company in the demo, and check a target against published buyer rules in about 20 seconds. When you need more than the preview, buy the list once, from $199 a list (the 3,000+ highest-scored companies), and score the biotechs you find outside it through the API in batches.